Lessons for Specialty Care Payment Reforms: Insights from Maryland’s GBR Model

By HEOR Staff Writer

July 7, 2023

 Maryland’s GBR model has been hailed as a game-changer in tackling the rising costs of healthcare. However, it’s crucial to recognize that payment reforms can have varying effects across different types of care. Here are some key takeaways for CMS’s new value-based specialty care strategy.

1️⃣ Tailored Payment Models: Specialty care savings may require specific payment models for different types of care, like cancer surgery. It’s essential to design reforms that cater to the unique needs of each specialty.

2️⃣ Nuanced Quality Measures: Quality assessment in specialty care should go beyond traditional metrics like readmissions and emergency visits. Patient-reported outcomes and person-centered measures should play a more significant role in evaluating care quality.

3️⃣ Health Equity Considerations: Specialty care reforms must address health equity. By separating reimbursement from volume, vulnerable populations can benefit from sustainable financing. The Global Equity Model offers a framework to assess the success of payment reforms based on health outcomes.

4️⃣ Policy Innovation: Replicating the success of Maryland’s GBR model requires policy innovation and alignment. Other states may need to establish cost growth targets or overcome implementation challenges to ensure viability.

5️⃣ Integration of Primary and Specialty Care: Meaningful delivery system changes are crucial to advancing the integration of primary and specialty care. Global budgets provide a foundation for reorganizing how specialty care is delivered and reimbursed.

There is much to learn from Maryland’s experience and drive effective payment reforms in specialty care. 

 

 

 

Reference url

Recent Posts

oncology market access strategy
Multistakeholder Approaches to Optimize Oncology Market Access Strategy

By João L. Carapinha

June 16, 2026

Effective oncology market access strategy has become markedly more complex as geopolitical pressures reshape how innovative cancer therapies reach patients, as made clear in Iroda Jurabekova’s pharma summit presentation. Determining whethe...
Real-World Evidence AI
Advancing Real-World Evidence AI in Medicines Regulation

By João L. Carapinha

June 16, 2026

The adoption of Real-World Evidence AI is reshaping how the European Medicines Agency evaluates medicines, according to the European Medicines Agency’s annual report. By moving these technologies from pilot project...
medicine shortages management
Strengthening Medicine Shortages Management for Enhanced Availability and Access

By João L. Carapinha

June 16, 2026

The European Medicines Agency made medicine shortages management a foundational policy objective in 2025, as highlighted in its annual reports and work programmes. By advancing coordinated shortages oversight and d...